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Sparse optimal control of a phase field tumour model with
mechanical effects
Harald Garcke ∗ Kei Fong Lam † Andrea Signori ‡
Abstract
In this paper, we study an optimal control problem for a macroscopic mechanical
tumour model based on the phase field approach. The model couples a Cahn–Hilliard
type equation to a system of linear elasticity and a reaction-diffusion equation for
a nutrient concentration. By taking advantage of previous analytical well-posedness
results established by the authors, we seek optimal controls in the form of a boundary
nutrient supply, as well as concentrations of cytotoxic and antiangiogenic drugs that
minimise a cost functional involving mechanical stresses. Special attention is given to
sparsity effects, where with the inclusion of convex non-differentiable regularisation
terms to the cost functional, we can infer from the first-order optimality conditions
that the optimal drug concentrations can vanish on certain time intervals.
Key words. Sparse optimal control, tumour growth, Cahn–Hilliard equation, linear elas-
ticity, mechanical effects, elliptic-parabolic system, optimality conditions
AMS subject classification. 49J20, 49K20, 35K57, 74B05, 35Q92.
1 Introduction
Mechanical stresses play a significant role in both enhancing and inhibiting the growth of
tumours. The unregulated proliferation of tumour cells displaces nearby normal tissues and
in turn these tissues exert externally applied stress to resist tumour expansion. In various
experimental studies (see [9, 25, 26, 44] and the references cited therein) high compressive
stress has the effect of suppressing proliferation and can induce apoptosis (natural cell
death) in tumour cells. However, in the case where the mechanical loads are not uniform,
tumours can adapt by growing in directions of least stress. Moreover, deformations of
the microenvironment brought about by these mechanical loads can alter the structure of
nearby blood and lymphatic vessels, which are responsible for supplying the region with
crucial nutrients, oxygen, therapeutic drugs, as well as drainage of excessive interstitial
fluids containing waste products. The gradual reduction in blood flow turns the stressed
region more hypoxic and more acidic, compounding with the reduction in nutrients levels
further accelerates the invasive and metastatic potentials of the tumours cells. On the
other hand this also impairs the effectiveness of immune cells or therapeutic agents as
they are not able to reach certain tumour regions in sufficient quantities. With the use
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of mathematical modelling [29, 43], treatments aimed at alleviating stress seem to be a
promising avenue that warrant further investigations and could be used in coordination
with other anti-cancer therapies.
Recent progress in mathematical oncology have shown promising results in forecasting
tumour growth and predictive simulations of treatments [1, 2, 32, 33, 34, 35]. Most mod-
els employ a continuum description involving partial differential equations to capture a
multitude of biological and chemical mechanisms. Among those we focus on the subclass
of phase field tumour models [13, 23, 38, 45], where the corresponding numerical simula-
tions (see, e.g., [14, 15, 17, 45, 46]) are able to replicate commonly observed morphologies
exhibited by tumours and their vasculatures.
While there has been a surge of activity in the subsequent mathematical modelling
and analysis of phase field tumour models, see [1, 11, 14, 15, 23, 38, 46] and the references
cited therein, there seems to comparatively fewer focus on mechanical interactions in
tumour growth within the subclass of phase field models, aside from recent contributions
[16, 22, 32, 33], see also [3, 5, 19, 20] for results concerning the related Cahn–Larche´ system.
In light of the significance of mechanical stress, for our study, we consider a simplification
of the phase field model that was proposed and studied in the authors’ previous work [22].
Consider a bounded domain Ω ⊂ Rd, d ∈ {2, 3}, with boundary Γ := ∂Ω that is either
of C1,1-regularity or is convex and is partitioned into two subregions ΓD and ΓN . For an
arbitrary T > 0 (which can be interpreted as the length of the medical treatment), the
following model posed in the space-time cylinder Ω × (0, T ) describes the evolution of a
cellular mixture containing tumour and non-tumour cells subject to various mechanisms
involving a chemical species acting as nutrient and mechanical stresses:
ϕt = ∆µ+ U(ϕ, σ, E(u)) in Q := Ω× (0, T ), (1.1a)
µ = −∆ϕ+Ψ′(ϕ)− χσ +W,ϕ(ϕ, E(u)) in Q, (1.1b)
W,ϕ(ϕ, E(u)) = −C(E(u)− E¯ − ϕE
∗) : E∗ (1.1c)
βσt = ∆σ + S(ϕ, σ) in Q, (1.1d)
0 = div(W,E(ϕ, E(u))) in Q, (1.1e)
W,E(ϕ, E(u)) = C(E(u)− E¯ − ϕE
∗) (1.1f)
ϕ(0) = ϕ0, σ(0) = σ0 in Ω, (1.1g)
0 = ∂nϕ = ∂nµ, ∂nσ + κ(σ − σB) = 0 on Σ := Γ× (0, T ), (1.1h)
u = 0 on ΣD := ΓD × (0, T ), (1.1i)
W,E(ϕ, E(u))n = g on ΣN := ΓN × (0, T ). (1.1j)
We refer the reader to [22, 32, 33] for more background on the model and related topics,
while briefly describe the main components. In the above, the variable ϕ denotes a phase
field parameter that serves to distinguish between the two different types of cellular ma-
terial in the mixture, with tumour cells occupying the region {ϕ = 1} and non-tumour
cells in the region {ϕ = −1}. The subsystem (1.1a)-(1.1b) constitutes a Cahn–Hilliard
type equation, where µ is the associated chemical potential. Coupled to this is a reaction-
diffusion equation (1.1d) for a nutrient σ, as well as a quasistatic linear elasticity system
(1.1e) with displacement u and symmetric strain tensor E(u) := 12(∇u + (∇u)
⊤). We
mention that there are certain cases where the nutrient evolves quasistatically, which is
covered by the case β = 0. The terms W,ϕ(ϕ, E(u)) and W,E(ϕ, E(u)) are partial deriva-
tives of the elastic energy W(ϕ, E(u)) with respect to its first and second arguments,
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respectively, and for this work we consider the choice
W(ϕ, E(u)) =
1
2
(E(u)− E¯ − ϕE∗) : C(E(u)− E¯ − ϕE∗),
where C is a constant, symmetric and positive definite elasticity tensor satisfying the usual
symmetry conditions, and the phase-dependent stress-free strain E¯(ϕ) under Vegard’s law
is given by the linear ansatz E¯(ϕ) = E¯+ϕE∗ with constant symmetric second order tensors
E¯ and E∗. Furthermore, in (1.1b) the directed movement of cells by chemotaxis is captured
by the term −χσ, with χ ≥ 0 playing the role of chemotactic sensitivity [23], while the
term Ψ′(ϕ) is the derivative of a double-well potential Ψ(ϕ) with equal minima at ϕ = ±1.
In our setting this term plays the role of cellular adhesion that leads to the development
of regions of tumour and non-tumour cells well-separated by interfacial layers described
by the set {−1 < ϕ < 1}.
For boundary conditions we subdivide the boundary Γ into the partition
Γ = ΓD ∪ ΓN such that ΓD ∩ ΓN = ∅.
Both portions are assumed to be relatively open and to have positive Hausdorff measures,
and on the portion ΓD, representing a rigid structure of the tumour environment such
as bone, the displacement u is set to be zero, and on the complement portion ΓN , the
normal component of the stress tensor W,E is equal to some given load g provided by a
fixed source. Meanwhile, (1.1h) highlights that the cellular diffusive flux ∂nµ is zero across
the boundary, and for κ > 0 the nutrient flux ∂nσ is proportional to the difference between
a nutrient source σB from nearby capillaries and the nutrient level at the boundary. The
case of a zero nutrient diffusive flux is covered by the choice κ = 0.
Lastly, the source term U(ϕ, σ, E(u)) in (1.1a) captures cellular growth that can be
influenced by nutrient concentration and mechanical stress. The example we will use is
U(ϕ, σ, E(u)) = λpσf(ϕ)g(W,E (ϕ, E(u))) − (λa +m(t))k(ϕ),
where λp ≥ 0, λa ≥ 0 are constant proliferation and apoptosis (cell death) rates, and f , g
and k are Lipschitz and bounded functions. For instance, we can model the proliferation
and apoptosis of tumour cells only by prescribing the conditions f(1) = k(1) = 1, f(−1) =
k(−1) = 0, see, e.g., [23]. Meanwhile, to account for the effect of reduced proliferation due
to increase in mechanical stress [4, 9, 25, 44], we may consider as a motivating example
the function g : Rd×d → R defined as
g(A) =
1√
1 + |A|2
for A ∈ Rd×d, (1.2)
where |A| is the Frobenius norm of the matrix A, so that as the magnitude of the stress
W,E(ϕ, E(u)) increases, the effects of the proliferation term λpσf(ϕ)g(W,E (ϕ, E(u))) be-
come less significant. This is different to the choice considered in [22] as the derivation
of optimal conditions in our present contribution requires a differentiable g. What is not
present in the previous work [22] is the coefficient m(t), and when paired with k(ϕ) we use
the productm(t)k(ϕ) to model a cytotoxic drug-induced decrease in tumour proliferation.
A motivating example for m(t) from [11] is
m(t) =
n∑
i=1
dce
−
t−Ti
τ H(t− Ti), (1.3)
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with drug dosage dc, drug delivery times Ti for i = 1, . . . , n, where n is the number of
chemotherapy cycles, τ denoting the mean lifetime of the drug and H is the Heaviside
function. After the i’th infusion, the effect of the drug decreases exponentially until the
next infusion at time Ti+1. For drugs with sufficiently short mean lifetime τ , or with large
enough infusion gap Ti − Ti−1, there are certain time intervals where the coefficient m is
close to zero.
Similarly, the source term S(ϕ, σ) in (1.1d) accounts for nutrient consumption and
transport to and from external capillaries. The example we will use is of the form
S(ϕ, σ) = −h(ϕ)(λcσ − s(t)) +B(σc − σ)
with constant consumption rate λc ≥ 0, capillary supply rate B ≥ 0, capillary nutrient
concentration σc and a Lipschitz, bounded function h. For instance, we can model nutrient
consumption only by the tumour cells by prescribing the conditions h(1) = 1 and h(−1) =
0. A new element absent from [22] is the coefficient s(t), which models the reduction in
nutrient supply caused by antiangiogenic therapy, and in [11] a similar form to (1.3) is
proposed for s(t), meaning that under suitable conditions, the coefficient s(t) take values
close to zero for certain time intervals.
It is common to prescribe cytotoxic drugs in chemotherapy that serve to disrupt the
cellular division process and promote apoptosis, but tumours can overcome these effects
by developing drug resistance or by generating new vasculatures through angiogenesis
to obtain nutrients that compensate any loss of mass from chemotherapy. Therefore, in
certain situations, it is of interest to combine two or more different therapies so that
their joint effect can account for more mechanisms that allows tumours to avoid complete
elimination, and have an overall larger positive impact on the treatment than the individual
monotherapies. Unfortunately, the results of various experimental and clinical studies
(see [36] and the references cited therein) have not produced clear guidelines on how to
proceed with combined therapies, in part due to the multitude of drugs presently available
and patient-specific interactions of multiple drugs. Hence, mathematicians and physicians
have turn towards the framework of optimal control to infer protocols, dosages and timings
that maximise tumour reduction and minimise harmful side-effects [27, 30, 31, 37, 39]. To
contribute to this effort, we study an optimal control problem with the model (1.1) as the
state system, and as controls we work with the boundary nutrient supply w1 = σB , the
cytotoxic coefficient w2 = m(t) and the antiangiogentic coefficient w3 = s(t). The cost
functional we consider is
J(ϕ,u, w1, w2, w3)
:=
αΩ
2
‖ϕ(T ) − ϕΩ‖
2
L2(Ω) +
αQ
2
‖ϕ− ϕQ‖
2
L2(Q) +
αE
2
ˆ
Q
n(x, ϕ)|W,E(ϕ, E(u))|
2 dx dt
+
γ1
2
‖w1‖
2
L2(Σ) +
γ2
2
‖w2‖
2
L2(0,T ) +
γ3
2
‖w3‖
2
L2(0,T )
+ γ4‖w2‖L1(0,T ) + γ5‖w3‖L1(0,T ). (1.4)
It is composed of the standard tracking-type with weights αQ, αΩ ≥ 0 and target functions
ϕQ : Q → R and ϕΩ : Ω → R, and L
2-regularisations for the optimal controls w1 = σB ,
w2 = m(t) and w3 = s(t) with corresponding weights γ1, γ2, γ3 ≥ 0. Let us stress that
the controls w2 and w3 are solely functions of time and are spatially constant. Compared
to previous works on the optimal control with phase field tumour models, we have the
presence of a term involving the the square of the stress W,E(ϕ, E(u)) weighted by a non-
negative coefficient n(x, ϕ) and constant αE ≥ 0. Due to the role of mechanical stresses on
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enhancing tumour growth, we are motivated to minimise stress accumulating in a certain
region of the domain, such as important organs (by taking n(x, ϕ) = χD(x) for a subregion
D ⊂ Ω where χD is the characteristic function of the set D), or in certain parts of the
tumour microenvironment whose location can be encoded with the help of the phase field
variable ϕ. One example is a function n(x, ϕ) = max(0,min(1, 12 (1 − ϕ))), so that n is
non-zero in the non-tumour region {ϕ = −1} and is zero in the tumour region {ϕ = 1}.
Moreover, we prescribe L1-regularisations of the drug concentrations w2 and w3 with
weights γ4, γ5 ≥ 0 to the cost functional (1.4), with the aim of using the combination
of both L2 and L1-regularisations to show sparsity, see Theorem 7 below for the precise
formulation. A first work on sparse controls with phase field tumour models is [41], where
directional sparsity [24] of the controls, i.e., sparsity w.r.t. space or w.r.t. time, is shown.
Our reasoning for such considerations is in part motivated by the common practice that
chemotherapies should be administrated to the patient only in very short periods of time
to avoid adverse side-effects. In the simulations performed in [12], where an optimal
control problem of a similar nature is studied with only L2-regularisation terms in the
cost functional, the optimal cytotoxic drug concentration is positive over the treatment
period. In practical applications this translates to prolonged exposure and subsequent
accumulation of the drugs in the body, potentially invoking damaging side-effects and
may even entail a premature abortion of the medical treatment.
The goal of this paper is to study the optimal control problem (1.4) subjected to the
state system (1.1). Building on the well-posedness results established in [22], we prove the
existence of a minimiser and derive first-order optimality conditions. Our main result is
sparsity of the optimal drug concentrations, brought about by the convex non-differentiable
L1-terms in (1.4). Compared to [41], our analysis includes the elasticity interactions in
(1.1b) and in (1.4), covering both cases of β > 0 and β = 0 in (1.1d) in a uniform manner,
as well as different sparsity conditions for non-negative drug concentrations m(t) and s(t).
We comment that tracking terms involving the nutrient concentration σ, such as
‖σ − σQ‖
2
L2(Q) or ‖σ(T ) − σΩ‖
2
L2(Ω) if β > 0, can also be inserted into the cost func-
tional. Other terms of interest include the total tumour volume at time T given by the
spatial integral of 12 (1+ϕ(T )), and thanks to the well-posedness result for (1.1) (see The-
orem 1 below) we can consider other parameters as control variables, for instance the
capillary nutrient concentration σc, the boundary load g, the initial data ϕ0, σ0 and the
coefficients χ, λp, λa, λc in (1.1) in the context of parameter estimation [18, 28], and even
the magnitude of the treatment time T [8, 21, 40]. One can also consider spatially varying
drug concentrations m(t, x) and s(t, x) as in [12, 41], and the corresponding analysis to
adapt to these elements would only require minor and straightforward modifications.
The rest of the paper is organised as follows: We recall previous results in Section 2,
and the existence of a minimiser to the optimal control problem is shown in Section 3.
Section 4 is devoted to the derivation of first-order optimality conditions, and in Section
5 we discuss the sparsity of controls.
2 Mathematical setting and previous results
2.1 Notation and useful preliminaries
The standard Lebesgue and Sobolev spaces over Ω are denoted by Lp := Lp(Ω) and
W k,p := W k,p(Ω) for any p ∈ [1,∞] and k > 0, with corresponding norms ‖ · ‖Lp and
‖ · ‖W k,p . In the case p = 2, these become Hilbert spaces and we use the notation H
k :=
Hk(Ω) = W k,2(Ω) and the norm ‖ · ‖Hk . For any Banach space Z, we denote its dual
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by Z ′, and the corresponding duality pairing by 〈·, ·〉Z . When Z = H
1(Ω), we use the
notation 〈·, ·〉 = 〈·, ·〉H1 . The L
2(Ω)-inner product is denoted by (·, ·), while the L2(Γ)
and L2(ΓN )-inner products are denoted by (·, ·)Γ and (·, ·)ΓN , respectively. We define the
Sobolev space H2
n
(Ω) as the set {f ∈ H2(Ω) : ∂nf = 0 on Γ}, and for the displacement
u, we introduce the following function space:
X(Ω) := {f ∈ H1(Ω)d : f
ΓD
= 0},
where by [10, Thm. 6.15-4, pp. 409–410], a Korn-type inequality is valid in X(Ω), i.e.,
there exists a constant CK > 0 such that
‖u‖H1 ≤ CK‖E(u)‖L2 ∀u ∈ X(Ω). (2.1)
2.2 Assumptions and previous results
In this work we make the following assumptions regarding parameters and functions in
the model:
(A1) Let g ∈ L2(ΓN )
d and σB ∈ L
∞(Σ) be given, while β,B, κ, χ, λa, λp, λc, σc are non-
negative constants such that at least one of {B,κ} is non-zero if β = 0. Moreover, E¯
and E∗ are constant symmetric second order tensors while C is a constant symmetric,
positive definite fourth order tensor satisfying
E : CE ≥ c0|E|
2
for all symmetric second order tensors E ∈ Rd×dsym with a positive constant c0.
(A2) The potential Ψ = Ψ1+Ψ2 is a non-negative function, Ψi ∈ C
3(R) for i = 1, 2, with
a convex non-negative function Ψ1 such that for all r, z ∈ R,
|Ψ′′2(r)| ≤ C, |Ψ
′′′
1 (r)| ≤ C(1 + |r|),
|Ψ′(r)−Ψ′(z)| ≤ C
(
1 + |r|2 + |z|2
)
|r − z|,
|Ψ′′(r)−Ψ′′(z)| ≤ C
(
1 + |r|+ |z|
)
|r − z|,
for some positive constant C.
(A3) The functions f , g, h and k satisfy f, h, k ∈ W 1,∞(R), g ∈ W 1,∞(Rd×d,R), with
Lipschitz constants that shall be denoted by a common symbol L > 0. Furthermore,
we assume h is non-negative.
(A4) The cytotoxic and antiangiogenic functions satisfy m, s ∈ L∞(0, T ).
(A5) The initial conditions satisfy ϕ0 ∈ H
1(Ω) and σ0 ∈ L
2(Ω) with 0 ≤ σ0 ≤ M :=
max(σc, ‖σB‖L∞(Σ)) a.e. in Ω.
To study the optimal control problem we will need the following:
(A6) We assume f , h, k ∈ C2(R)∩W 2,∞(R), g ∈ C2(Rd×d,R)∩W 2,∞(Rd×d,R) and
n : Ω × R → R is a Carathe´odory function such that n(x, ·) ∈ C1(R) ∩W 1,∞(R) is
non-negative for a.e. x ∈ Ω.
(A7) The coefficients αQ, αΩ, αE , γ1, γ2, γ3, γ4, γ5 are non-negative constants, not all zero.
Moreover, γ2 is positive if γ4 is positive and γ3 is positive when γ5 is positive.
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(A8) The objective data ϕQ : Q → R, ϕΩ : Ω → R are given functions satisfying ϕQ ∈
L2(Q), ϕΩ ∈ L
2(Ω).
It is worth noting that the conditions expressed in (A2) are fulfilled by the classical quartic
potential Ψ(r) = 14(r
2 − 1)2. For the motivating example (1.2), for any A ∈ Rd×d, we use
the notation g′(A) to denote the tensor derivative of g, i.e., g′(A) is a second order tensor
with
[g′(A)]ij =
∂
∂Aij
g(A) = −
Aij
(1 + |A|2)3/2
for 1 ≤ i, j ≤ d.
On the other hand, we use the notation g′′(A) to denote the Hessian of g, which is a fourth
order tensor defined as
[g′′(A)]ijkl =
∂2
∂Aij∂Akl
g(A) =
3AijAkl
(1 + |A|2)5/2
−
δikδjl
(1 + |A|2)3/2
for 1 ≤ i, j, k, l ≤ d.
Hence, it is easy to see that for any A ∈ Rd×d, both |[g′(A)]ij | and |[g
′′(A)]ijkl| are
bounded for all 1 ≤ i, j, k, l ≤ d. In particular, we can infer that |g′(W,E(ϕ, E(u)))| and
|g′′(W,E(ϕ, E(u))| are bounded a.e. in Q thanks to (A3). For the rest of the paper, the
parameters β, g, B, κ, χ, λa, λp, λc, σc, C, E¯ , E
∗, as well as initial data ϕ0 and σ0 are
kept fixed. We then introduce the notation
w = (w1, w2, w3),
and the set of admissible controls Uad = U
(1)
ad × U
(2)
ad × U
(3)
ad as
U
(1)
ad := {w1 ∈ L
∞(Σ) : w1 ≤ w1 ≤ w1 a.e. on Σ},
U
(i)
ad := {wi ∈ L
∞(0, T ) : wi ≤ wi ≤ wi a.e. in (0, T )} for i = 2, 3,
(2.2)
with fixed w1, w1 ∈ L
∞(Σ), w2, w2, w3, w3 ∈ L
∞(0, T ) such that w1 ≤ w1 a.e. on Σ, wi ≤
wi a.e. in (0, T ) for i = 2, 3, and max(‖w1‖L∞(Σ), ‖w1‖L∞(Σ)) ≤M . The admissible set of
controls Uad is a non-empty, closed and convex subset of U := L
2(Σ)×L2(0, T )×L2(0, T ),
and we can find a positive constant R such that
UR := {(w1, w2, w3) ∈ U : ‖w1‖L2(Σ) + ‖w2‖L2(0,T ) + ‖w3‖L2(0,T ) < R} ⊃ Uad.
The following result concerns the well-posedness of the model (1.1).
Theorem 1. Under (A1)-(A5) there exists a unique weak solution (ϕ, µ, σ,u) to (1.1)
and an exponent p > 2 such that
ϕ ∈ H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;H1(Ω)) ∩ L2(0, T ;H2
n
(Ω)),
µ ∈ L2(0, T ;H1(Ω)),
σ ∈ L2(0, T ;H1(Ω)) ∩ L∞(0, T ;L∞(Ω)) with 0 ≤ σ ≤M a.e. in Q,
and σ ∈ H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;L2(Ω)) if β > 0,
u ∈ L∞(0, T ;X(Ω) ∩W 1,p(Ω)),
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with ϕ(0) = ϕ0 in L
2(Ω) as well as σ(0) = σ0 in L
2(Ω) if β > 0, and
0 =
ˆ T
0
〈ϕt, ζ〉+ (∇µ,∇ζ)− (U(ϕ, σ, E(u)), ζ) dt, (2.3a)
0 =
ˆ T
0
(µ, ζ)− (∇ϕ,∇ζ)− (Ψ′(ϕ), ζ) + χ(σ, ζ)− (W,ϕ(ϕ, E(u)), ζ) dt, (2.3b)
0 =
ˆ T
0
β〈σt, ζ〉+ (∇σ,∇ζ) + κ(σ − σB, ζ)Γ − (S(ϕ, σ), ζ) dt, (2.3c)
0 =
ˆ T
0
(C(E(u)− E¯ − ϕE∗),∇η)− (g,η)ΓN dt (2.3d)
for all ζ ∈ L2(0, T ;H1(Ω)) and η ∈ L2(0, T ;X(Ω)). Moreover, there exists a positive
constant K1 independent of β such that
‖ϕ‖H1(0,T ;H1(Ω)′)∩L∞(0,T ;H1)∩L2(0,T ;H2) + ‖µ‖L2(0,T ;H1)
+ ‖σ‖L2(0,T ;H1) + β
1
2‖σ‖H1(0,T ;H1(Ω)′)∩L∞(0,T ;L2)
+ ‖u‖L∞(0,T ;X(Ω)∩W 1,p(Ω)) ≤ K1
(
1 + β
1
2 ‖σ0‖L2
)
.
(2.4)
For any pair {(ϕi, µi, σi,ui)}i=1,2 of weak solutions to (1.1) corresponding to data
{(ϕ0,i, σ0,i,gi, σB,i,mi, si)}i=1,2,
there exists a positive constant K2 independent of the differences of {(ϕi, µi, σi,ui)}i=1,2
and β such that
‖ϕ1 − ϕ2‖L∞(0,T ;H1)∩L2(0,T ;H2) + ‖µ1 − µ2‖L2(0,T ;H1) + ‖σ1 − σ2‖L2(0,T ;H1)
+ β
1
2 ‖σ1 − σ2‖L∞(0,T ;L2) + ‖u1 − u2‖L∞(0,T ;X(Ω))
≤ K2
(
‖ϕ0,1 − ϕ0,2‖H1 + β
1
2 ‖σ0,1 − σ0,2‖L2 + ‖g1 − g2‖L2(ΓN )
)
+K2
(
‖σB,1 − σB,2‖L2(Σ) + ‖m1 −m2‖L2(0,T ) + ‖s1 − s2‖L2(0,T )
)
.
(2.5)
Remark 2.1. The proof of existence can be deduced analogously from [22, Sec. 3], and we
comment that the subsequent constant K1 in (2.4) is bounded uniformly in (σB ,m(t), s(t))
when we restrict to the open set UR. Whereas a minor modification of [22, Sec. 6] using the
boundedness of k and h yields the above continuous dependence assertion in the presence
of the new coefficients m(t) and s(t). Hence, we omit the details.
Remark 2.2. A closer inspection of the proof in [22, Sec. 5.2] allows us to deduce the
further regularity statement
ϕ ∈ L4(0, T ;H2
n
(Ω)).
We briefly sketch the argument. Testing (1.1b) with −∆ϕ, integrating by parts for the
terms involving µ and Ψ′(ϕ), then using the convexity of Ψ1, the bounds for Ψ
′′
2, the
boundedness of σ, and the regularity ϕ ∈ L∞(0, T ;H1(Ω)) and u ∈ L∞(0, T ;X(Ω)),
1
2‖∆ϕ‖
2
L2 ≤ ‖∇µ‖L2‖∇ϕ‖L2 + C‖∇ϕ‖
2
L2 + C‖σ‖
2
L2 + C‖W,ϕ(ϕ, E(u))‖
2
L2
≤ C
(
1 + ‖∇µ‖L2
)
.
Squaring and integrating over (0, T ) yields that ∆ϕ ∈ L4(0, T ;L2(Ω)) and elliptic regularity
gives the assertion.
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3 The optimal control problem
In this section we show that there exists at least one minimiser to the optimal control
problem minimising the cost functional (1.4) with state system given by (1.1). By Theorem
1, we can define the control-to-state operator S which assigns every admissible control
w = (w1, w2, w3) = (σB ,m, s) the corresponding unique solution (ϕ, µ, σ,u) to (1.1).
Namely, we have
S : Uad ⊂ UR → Y
β, (w1, w2, w3) 7→ (ϕ, µ, σ,u),
where the solution space Yβ is defined, according to Theorem 1, as
Yβ :=


H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;H1(Ω)) ∩ L2(0, T ;H2
n
(Ω))× L2(0, T ;H1(Ω))
×H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;L2(Ω)) ∩ L2(0, T ;H1(Ω)) ∩ L∞(Q)
×L∞(0, T ;X(Ω) ∩W 1,p(Ω)) if β > 0,
H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;H1(Ω)) ∩ L2(0, T ;H2
n
(Ω))× L2(0, T ;H1(Ω))
×L2(0, T ;H1(Ω)) ∩ L∞(Q)
×L∞(0, T ;X(Ω) ∩W 1,p(Ω)) if β = 0.
Denoting by S1(w) = ϕ the first component and by S4(w) = u the fourth component, we
can define the reduced cost functional as
J (w) = J(S1(w),S4(w),w).
Theorem 2. Under (A1)-(A8), there exists at least one minimiser w = (w1, w2, w3) ∈ Uad
to the optimal control problem
min
(z1,z2,z3)∈Uad
J (z1, z2, z3).
Since the proof is somewhat standard we omit the details and sketch the main points.
The non-negativity of J implies the infimum infUad J exists and allows us to find a min-
imising sequence {wn = (w1,n, w2,n, w3,n)}n∈N ⊂ Uad such that J (wn) → infUad J as
n→∞. Denoting the corresponding solution as (ϕn, µn, σn,un) = S(wn) ∈ Y
β , we infer
by the bound (2.4) that {(ϕn, µn, σn,un)}n∈N is uniformly bounded in Y
β . Hence, along
a non-relabelled subsequence there exists a limit triplet w = (w1, w2, w3) ∈ Uad such that,
as n→∞,
(w1,n, w2,n, w3,n)→ (w1, w2, w3) weakly* in L
∞(Σ)× L∞(0, T )× L∞(0, T ),
(ϕn, µn, σn,un)→ (ϕ, µ, σ,u) = S(w) weakly* in Y
β .
The Aubin–Lions compactness theorem then yields the strong convergence of ϕn to ϕ in
C0([0, T ];L2(Ω)), allowing us to pass to the limit in the tracking terms of J and provides
strong convergence
√
n(ϕn)η →
√
n(ϕ)η for all η ∈ L2(Q). Together with the weak
convergence of E(un) to E(u) in L
2(Q), we arrive at the weak convergence√
n(ϕn)W,E(ϕn, E(un))→
√
n(ϕ)W,E(ϕ, E(u)) weakly in L
2(Q).
Then, by the weak lower semicontinuity of Lp-norms for p ∈ [1,∞), we deduce that
J (w) ≤ lim inf
n→∞
J (wn) = inf
Uad
J .
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4 First-order necessary optimality conditions
Theorem 3. Under (A1)-(A8), let w∗ = (w∗1, w
∗
2 , w
∗
3) ∈ Uad be an optimal control with
associated state (ϕ, µ, σ,u) = S(w∗). Then, there exist functions λ2, λ3 ∈ L
∞(0, T ) such
that, for a.e. t ∈ (0, T ),
λi(t) ∈


{1} if w∗i (t) > 0,
[−1, 1] if w∗i (t) = 0,
{−1} if w∗i (t) < 0,
for i ∈ {2, 3}, (4.1)
and for all y = (y1, y2, y3) ∈ Uad,
0 ≤
ˆ T
0
(κr + γ1w
∗
1, y1 − w
∗
1)Γ dt+
ˆ T
0
(γ2w
∗
2 + γ4λ2 −
ˆ
Ω
k(ϕ)p dx)(y2 − w
∗
2) dt
+
ˆ T
0
(γ3w
∗
3 + γ5λ3 +
ˆ
Ω
h(ϕ)r dx)(y3 − w
∗
3) dt,
(4.2)
where p and r are the first and third components of the associated adjoint variables
(p, q, r, s) satisfying the adjoint system (4.15).
The proof of Theorem 3 proceeds in four steps, which is covered in the following four
subsections.
4.1 Linearised state system
Given w∗ = (w∗1, w
∗
2 , w
∗
3) ∈ Uad with associated state (ϕ, µ, σ,u) = S(w
∗) ∈ Yβ , for
arbitrary h = (h1, h2, h3) ∈ U , we study the following linearised state system:
ξt = ∆η + Ulin(ϕ, σ, E(u), w
∗
2 , h2, ξ, ψ, E(v)) in Q, (4.3a)
Ulin = λpg(W,E(ϕ, E(u)))(f
′(ϕ)ξσ + f(ϕ)ψ) (4.3b)
+ λpσf(ϕ)g
′(W,E(ϕ, E(u))) : C(E(v)− ξE
∗)
− (λa + w
∗
2)k
′(ϕ)ξ − h2k(ϕ)
η = −∆ξ +Ψ′′(ϕ)ξ − χψ − C(E(v)− ξE∗) : E∗ in Q, (4.3c)
βψt = ∆ψ + Slin(ϕ, σ,w
∗
3 , h3, ξ, ψ) in Q, (4.3d)
Slin = −h
′(ϕ)ξ(λcσ − w
∗
3)− h(ϕ)(λcψ − h3)−Bψ (4.3e)
0 = div(C(E(v) − ξE∗)) in Q, (4.3f)
0 = ξ(0) = ψ(0) in Ω, (4.3g)
0 = ∂nξ = ∂nη, ∂nψ + κ(ψ − h1) = 0 on Σ, (4.3h)
v = 0 on ΣD, (4.3i)
0 = C(E(v) − ξE∗)n on ΣN . (4.3j)
Introducing the solution space
Yβlin =


H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;H1(Ω)) ∩ L2(0, T ;H2
n
(Ω))× L2(0, T ;H1(Ω))
×H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;L2(Ω)) ∩ L2(0, T ;H1(Ω))
×L∞(0, T ;X(Ω)) if β > 0,
H1(0, T ;H1(Ω)′) ∩ L∞(0, T ;H1(Ω)) ∩ L2(0, T ;H2
n
(Ω))× L2(0, T ;H1(Ω))
×L2(0, T ;H1(Ω))× L∞(0, T ;X(Ω)) if β = 0,
we have the following result.
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Theorem 4. For given w∗ = (w∗1 , w
∗
2, w
∗
3) ∈ Uad with (ϕ, µ, σ,u) = S(w
∗) ∈ Yβ and
h = (h1, h2, h3) ∈ U , under (A1)-(A6), there exists a unique solution (ξ, η, ψ,v) ∈ Y
β
lin to
(4.3) with ξ(0) = 0, ψ(0) = 0 if β > 0, and
0 =
ˆ T
0
〈ξt, ζ〉+ (∇η,∇ζ)− (Ulin(ϕ, σ, E(u), w
∗
2 , h2, ψ, ξ, E(v)), ζ) dt, (4.4a)
0 =
ˆ T
0
(η −Ψ′′(ϕ)ξ + χψ + C(E(v)− ξE∗) : E∗, ζ)− (∇ξ,∇ζ) dt, (4.4b)
0 =
ˆ T
0
β〈ψt, ζ〉+ (∇ψ,∇ζ) + κ(ψ − h1, ζ)Γ − (Slin(ϕ, σ,w
∗
3 , h3, ξ, ψ), ζ) dt, (4.4c)
0 =
ˆ T
0
(C(E(v) − ξE∗),∇η) dt, (4.4d)
for all ζ ∈ L2(0, T ;H1(Ω)) and η ∈ L2(0, T ;X(Ω)).
Proof. We proceed with formal estimates that can be justified rigorously with a Galerkin
approximation. In the following the positive constants denoted by the symbol C will
be independent of the Galerkin parameter, as well as h1, h2 and h3 and might change
from line to line. Besides, let us remark that since w∗ is fixed, the corresponding state
(ϕ, µ, σ,u)= S(w∗) enjoys the bound (2.4). Let us mention that uniqueness follows from
existence thanks to the linearity of the system (4.3).
We test (4.4a) with η and Kξ, (4.4b) with −ξt and η, (4.4c) with Rψ and (4.4d) with
vt for positive constants K,R to be determined later. After summing and rearranging we
get
1
2
d
dt
(
K‖ξ‖2L2 + ‖∇ξ‖
2
L2 +Rβ‖ψ‖
2
L2
)
+
d
dt
ˆ
Ω
W lin(ξ, E(v)) dx
+‖η‖2H1 +R‖∇ψ‖
2
L2 +Rκ‖ψ‖
2
L2
Γ
+RB‖ψ‖2L2
= −K(∇η,∇ξ) + (Ulin, η +Kξ) + (Ψ
′′(ϕ)ξ, η − ξt) + χ(ψ, ξt − η)
+ (∇ξ,∇η) − (C(E(v)− ξE∗) : E∗, η) +Rκ(h1, ψ)Γ +R(Slin, ψ)
(4.5)
where
W lin(ξ, E(v)) =
1
2
(E(v)− ξE∗) : C(E(v)− ξE∗),
and we have used the identity
d
dt
ˆ
Ω
W lin(ξ, E(v)) dx = (W lin,ξ (ξ, E(v)), ξt) + (W
lin
,E (ξ, E(v)), E(vt))
= −(C(E(v)− ξE∗) : E∗, ξt) + (C(E(v)− ξE
∗), E(vt))
derived with the help of the symmetry of C and E∗. Furthermore, by the positive definite-
ness of C and Young’s inequality,
W lin(ξ, E(v)) ≥
c0
4
‖E(v)‖2L2 − C
(
1 + ‖ξ‖2L2
)
. (4.6)
Next, recalling that w∗2 and w
∗
3 are constant in space, from the definition of Ulin and
Slin, using the boundedness of w
∗
2, w
∗
3, f , g, h, k and their derivatives, as well as the
boundedness of σ, and of |g′(W,E(ϕ, E(u)))|, it is easy to see that
‖Ulin‖L2 ≤ C
(
‖ξ‖L2 + ‖ψ‖L2 + ‖E(v)‖L2 + |h2|
)
, (4.7)
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while
R(Slin, ψ) ≤ −R
(
B‖ψ‖2L2 + λc(h(ϕ)ψ,ψ)
)
+RC
(
‖ξ‖L2 + |h3|
)
‖ψ‖L2
≤ C
(
‖ξ‖2L2 + |h3|
2
)
+ ‖ψ‖2L2 ,
where we also use that the first two terms on the right-hand side are non-positive. Also,
using (A2), the continuous inclusion V ⊂ L6(Ω), and the fact that ϕ ∈ L∞(0, T ;H1(Ω)),
‖Ψ′′(ϕ)ξ‖2L2 ≤ C‖ξ‖
2
L6
(
1 + ‖ϕ‖4L6
)
≤ C‖ξ‖2H1 .
Hence, the right-hand side of (4.5) can be estimated as follows:
RHS ≤
1
4
‖η‖2H1 + c‖ψ‖
2
L2 + C
(
‖ξ‖2H1 + ‖E(v)‖
2
L2 + ‖h1‖
2
L2
Γ
+ |h2|
2 + |h3|
2
)
+ (χψ −Ψ′′(ϕ)ξ, ξt) +
Rκ
2
‖ψ‖2L2
Γ
−RB‖ψ‖2L2
with a positive constant c that is independent of R. To handle the term involving ξt, we
use (4.4a) and (4.7) to deduce that
‖ξt‖H1(Ω)′ ≤ ‖∇η‖L2 + ‖Ulin‖L2
≤ ‖∇η‖L2 + C
(
‖ξ‖L2 + ‖ψ‖L2 + ‖E(v)‖L2 + |h2|
)
,
(4.8)
while invoking the assumption (A2) for Ψ′′ and Ψ′′′ leads to
‖Ψ′′(ϕ)ξ‖H1 ≤ ‖Ψ
′′(ϕ)ξ‖L2 + ‖ξΨ
′′′(ϕ)∇ϕ‖L2 + ‖Ψ
′′(ϕ)∇ξ‖L2
≤ C‖ξ‖H1 + ‖Ψ
′′′(ϕ)‖L6‖ξ‖L6‖∇ϕ‖L6 + ‖Ψ
′′(ϕ)‖L∞‖∇ξ‖L2
≤ C
(
1 + ‖ϕ‖2H2
)
‖ξ‖H1 .
Then, via Young’s inequality
|(Ψ′′(ϕ)ξ, ξt)| ≤
1
8
‖∇η‖2L2 + C
(
1 + ‖ϕ‖4H2
)
‖ξ‖2H1 + C
(
‖ψ‖2L2 + ‖E(v)‖
2
L2 + |h2|
2
)
.
Meanwhile, by a similar argument,
|(χψ, ξt)| ≤
1
8
‖∇η‖2L2 + C
(
‖ψ‖2H1 + ‖E(v)‖
2
L2 + |h2|
2 + ‖ξ‖2L2
)
,
and so collecting the above estimates for the right-hand side of (4.5) we deduce the exis-
tence of two positive constants c1 and c2 independent of R such that
1
2
d
dt
(
K‖ξ‖2L2 + ‖∇ξ‖
2
L2 +Rβ‖ψ‖
2
L2
)
+
d
dt
ˆ
Ω
W lin(ξ, E(v)) dx
+
1
2
‖η‖2H1 + (R− c1)‖∇ψ‖
2
L2 +
Rκ
2
‖ψ‖2L2
Γ
+ (RB − c2)‖ψ‖
2
L2
≤ C
(
1 + ‖ϕ‖4H2
)(
‖E(v)‖L2 + ‖ξ‖
2
H1
)
+ C
(
‖h1‖
2
L2
Γ
+ |h2|
2 + |h3|
2
)
≤ C
(
1 + ‖ϕ‖4H2
)(
‖W lin(ξ, E(v))‖L1 + ‖ξ‖
2
H1
)
+ C
(
‖h1‖
2
L2
Γ
+ |h2|
2 + |h3|
2
)
,
where we have also used the lower bound (4.6). In the case β > 0 we can directly employ
Gronwall’s inequality to handle the terms on the right-hand side, whereas in the case
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β = 0 we proceed as follows: if B > 0, we can choose R > max(2c1,
2c2
B ), and if B = 0
then κ > 0 by (A1) and we employ the generalised Poincare´ inequality
‖f‖L2 ≤ C
(
‖∇f‖L2 + ‖f‖L2
Γ
)
∀f ∈ H1(Ω)
to handle the term c2‖ψ‖
2
L2 on the left-hand side after choosing R sufficiently large. In-
voking Gronwall’s inequality, keeping in mind that ϕ ∈ L4(0, T ;H2(Ω)), there exists a
constant C independent of β such that
‖ξ‖2L∞(0,T ;H1) + β‖ψ‖
2
L∞(0,T ;L2) + ‖W
lin(ξ, E(v))‖2L∞(0,T ;L1)
+ ‖η‖2L2(0,T ;H1) + ‖∇ψ‖
2
L2(Q) + κ‖ψ‖
2
L2(Σ) +B‖ψ‖
2
L2(Q)
≤ C
(
‖h1‖
2
L2(Σ) + ‖h2‖
2
L2(0,T ) + ‖h3‖
2
L2(0,T )
)
.
(4.9)
In view of ξ(0) = 0, we note that from (4.3) the initial data v0 assigned to v satisfies the
elliptic equation 

div(C(E(v0))) = 0 in Ω,
v0 = 0 on ΓD,
C(E(v0))n = 0 on ΓN .
Testing with v0 and using Korn’s inequality shows that
‖v0‖H1 ≤ CK‖E(v0)‖L2 ≤
CK
c0
(CE(v0), E(v0)) = 0,
which explains the absence of initial data on the right-hand side of (4.9). Then, recalling
the lower bound (4.6) and employing Korn’s inequality we have
‖ξ‖2L∞(0,T ;H1) + β‖ψ‖
2
L∞(0,T ;L2) + ‖v‖
2
L∞(0,T ;H1) + ‖η‖
2
L2(0,T ;H1) + ‖ψ‖
2
L2(0,T ;H1)
≤ C
(
‖h1‖
2
L2(Σ) + ‖h2‖
2
L2(0,T ) + ‖h3‖
2
L2(0,T )
)
,
which also implies the uniqueness of solution since the difference of two solutions to the
linear system (4.3) satisfies (4.3) with h1 = h2 = h3 = 0. To complete the proof we return
to (4.8) to deduce that
‖ξt‖L2(0,T ;H1(Ω)′) ≤ C
(
‖h1‖L2(Σ) + ‖h2‖L2(0,T ) + ‖h3‖L2(0,T )
)
,
while if β > 0, from (4.4c) we also have
‖ψt‖L2(0,T ;H1(Ω)′) ≤ C
(
‖h1‖L2(Σ) + ‖h2‖L2(0,T ) + ‖h3‖L2(0,T )
)
.
Lastly after passing to the limit in the Galerkin approximation we obtain limit functions
(ξ, η, ψ,v) ∈ Yβlin satisfying (4.3) except for the L
2(0, T ;H2
n
(Ω)) regularity of ξ. This can
be obtained from viewing (4.4b) as the variational formulation of the elliptic problem{
−∆ξ = f˜ : = η −Ψ′′(ϕ)ξ + χψ + C(E(v) − ξE∗) : E∗ in Q,
∂nξ = 0 on Σ,
with a right-hand side f˜ ∈ L2(Q), and with the help of elliptic regularity we then infer
that ξ ∈ L2(0, T ;H2
n
(Ω)). Hence, we have shown that (ξ, η, ψ,v) ∈ Yβlin and this concludes
the proof.
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4.2 Differentiability of the solution operator
In this section we establish the Fre´chet differentiability of the solution operator S between
suitable Banach spaces, and that the derivative at w∗ = (w∗1, w
∗
2, w
∗
3) ∈ Uad in direction
h = (h1, h2, h3) ∈ U is the unique solution (ξ, η, ψ,v) obtained from Theorem 4. This is
formulated as follows.
Theorem 5. Under (A1)-(A6), for given w∗ ∈ Uad with (ϕ, µ, σ,u) = S(w
∗) ∈ Yβ , the
control-to-state operator S is Fre´chet differentiable at w∗ when viewed as a mapping from
U to X β , where
X β =


L∞(0, T ;L2(Ω)) ∩ L2(0, T ;H2
n
(Ω))× L2(Q)
×L∞(0, T ;L2(Ω)) ∩ L2(0, T ;H1(Ω))× L2(0, T ;X(Ω)) if β > 0,
L∞(0, T ;L2(Ω)) ∩ L2(0, T ;H2
n
(Ω))× L2(Q)
×L2(0, T ;H1(Ω))× L2(0, T ;X(Ω)) if β = 0.
Moreover, for all h = (h1, h2, h3) ∈ U , the directional derivative
DS(w∗)[h] = (ξ, η, ψ,v)
is the unique solution to (4.3) associated to h.
Proof. We denote
(ϕh, µh, σh,uh) = S(w
∗ + h),
and aim to show
‖S(w∗ + h)− S(w∗)−DS(w∗)[h]‖Xβ
‖h‖U
→ 0 as ‖h‖U → 0.
This is done via establishing for functions
Φ := ϕh − ϕ− ξ, λ := µh − µ− η, θ := σh − σ − ψ, z := uh − u− v
the inequality
‖(Φ, λ, θ,z)‖Xβ ≤ C‖h‖
2
U (4.10)
with a positive constant C independent of (Φ, λ, θ,z) and h. To this end, we recall from
Theorem 1 and Theorem 4 that the new variables (Φ, λ, θ,z) ∈ Yβlin satisfy
0 = 〈Φt, ζ〉+ (∇λ,∇ζ) + (λpXh, ζ) (4.11a)
− ((λa + w
∗
2)[k(ϕh)− k(ϕ)− k
′(ϕ)ξ], ζ) − ((k(ϕh)− k(ϕ))h2, ζ)
0 = (λ, ζ)− (∇Φ,∇ζ)− (Ψ′(ϕh)−Ψ
′(ϕ)−Ψ′′(ϕ)ξ, ζ) (4.11b)
+ (χθ, ζ)− (C(E(z) −ΦE∗) : E∗, ζ),
0 = β〈θt, ζ〉+ (∇θ,∇ζ) + (Bθ + λch(ϕ)θ, ζ) + (κθ, ζ)Γ (4.11c)
+ λc((σ − w
∗
3)[h(ϕh)− h(ϕ) − h
′(ϕ)ξ], ζ) − λc((h(ϕh)− h(ϕ))h3, ζ),
+ λc((h(ϕh)− h(ϕ))(σh − σ), ζ)
0 = (C(E(z) − ΦE∗),∇η), (4.11d)
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for all ζ ∈ H1(Ω) and η ∈ X(Ω) and for a.e. t ∈ (0, T ), where
Xh =
(
g(W,E(ϕh, E(uh))) − g(W,E (ϕ, E(u)))
)
×
[
(f(ϕh)− f(ϕ))(σh − σ) + f(ϕ)(σh − σ) + (f(ϕh)− f(ϕ))σ
]
+ g(W,E(ϕ, E(u)))
×
[
(f(ϕh)− f(ϕ))(σh − σ) + σ[f(ϕh)− f(ϕ)− f
′(ϕ)ξ] + f(ϕ)θ
]
+ f(ϕ)σ
[
g(W,E (ϕh, E(uh)))− g(W,E (ϕ, E(u))) − g
′(W,E(ϕ, E(u))) : C(E(v)− ξE
∗)
]
.
Take note that h1 does not appear in (4.11) since the state system (1.1) is linear in
w∗1 = σB. We invoke Taylor’s theorem with integral remainder for f ∈W
2,∞(R):
f(x)− f(a)− f ′(a)(x − a) = (x− a)2
ˆ 1
0
f ′′(a+ z(x− a))(1 − z) dz for a, x ∈ R,
to deduce that
f(ϕh)− f(ϕ)− f
′(ϕ)ξ = f ′(ϕ)Φ + (ϕh − ϕ)
2Rf ,
h(ϕh)− h(ϕ) − h
′(ϕ)ξ = h′(ϕ)Φ + (ϕh − ϕ)
2Rh,
k(ϕh)− k(ϕ)− k
′(ϕ)ξ = k′(ϕ)Φ + (ϕh − ϕ)
2Rk,
Ψ′(ϕh)−Ψ
′(ϕ) −Ψ′′(ϕ)ξ = Ψ′′(ϕ)Φ + (ϕh − ϕ)
2RΨ,
where
Rf =
ˆ 1
0
f ′′(ϕ+ z(ϕh − ϕ))(1 − z) dz, Rh =
ˆ 1
0
h′′(ϕ+ z(ϕh − ϕ))(1 − z) dz,
Rk =
ˆ 1
0
k′′(ϕ+ z(ϕh − ϕ))(1 − z) dz, RΨ =
ˆ 1
0
Ψ′′′(ϕ+ z(ϕh − ϕ))(1 − z) dz,
and in light of the regularity assumption (A6), as well as (A2) and (2.4), there exists a
positive constant C such that
‖Rf‖L∞+‖Rh‖L∞ + ‖Rk‖L∞ ≤ C, ‖RΨ‖L6 ≤ C
(
1 + ‖ϕ‖L6 + ‖ϕh‖L6
)
≤ C. (4.12)
Next, we test (4.11a) with Φ, (4.11b) with λ, (4.11c) with Mθ and (4.11d) with Kz for
positive constants M,K yet to be determined, and upon adding the resulting equations
we arrive at
1
2
d
dt
(
‖Φ‖2L2 + βM‖θ‖
2
L2
)
+ ‖λ‖2L2 +M‖∇θ‖
2
+M(Bθ + λch(ϕ)θ, θ) +Mκ‖θ‖
2
L2
Γ
+Kc0‖E(z)‖
2
≤ −(λpXh,Φ) +
(
(λa + w
∗
2)[k(ϕh)− k(ϕ) − k
′(ϕ)ξ] + h2(k(ϕh)− k(ϕ)),Φ
)
+ (Ψ′(ϕh)−Ψ
′(ϕ) −Ψ′′(ϕ)ξ, λ) − (χθ, λ) + (C(E(z) − ΦE∗) : E∗, λ)
−Mλc((σ − w
∗
3)[h(ϕh)− h(ϕ)− h
′(ϕ)ξ], θ) +Mλc((h(ϕh)− h(ϕ))h3, θ)
−Mλc((h(ϕh)− h(ϕ))(σh − σ), θ) +K(C(ΦE
∗),E(z)).
(4.13)
Looking at the terms involving z, we see
(C(E(z) − ΦE∗) : E∗, λ) +K(C(ΦE∗),E(z)) ≤
1
8
‖λ‖2L2 + C‖E(z)‖
2
L2 +C(1 +K
2)‖Φ‖2L2
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for a positive constant C independent of K. Next, for terms involving θ, we employ the
boundedness of σ and w∗3, and the Lipschitz continuity of h to obtain
− (χθ, λ)−Mλc((h(ϕh)− h(ϕ))(σh − σ), θ)
−Mλc((σ −w
∗
3)[h(ϕh)− h(ϕ)− h
′(ϕ)ξ], θ) +Mλc((h(ϕh)− h(ϕ))h3, θ)
≤
1
8
‖λ‖2L2 + C‖θ‖
2
L2 +M
2C‖ϕh − ϕ‖
2
L4‖σh − σ‖
2
L4
+M2C‖h′′(ϕ)Φ + (ϕh − ϕ)
2Rh‖
2
L2 +M
2C‖ϕh − ϕ‖
2
L2 |h3|
2
≤
1
8
‖λ‖2L2 + C‖θ‖
2
L2 + CM
2
(
‖Φ‖2L2 + ‖ϕh − ϕ‖
2
H1
(
‖σh − σ‖
2
H1 + ‖ϕh − ϕ‖
2
H1 + |h3|
2
))
for a positive constant C independent of M . Next, for the terms involving k in (4.13) we
similarly have
((λa + w
∗
2)[k(ϕh)− k(ϕ) − k
′(ϕ)ξ] + h2(k(ϕh)− k(ϕ)),Φ)
≤ C‖Φ‖2L2 + C‖ϕh − ϕ‖
4
L4 + C‖ϕh − ϕ‖
2
L2 |h2|
2
≤ C‖Φ‖2L2 + C
(
|h2|
2 + ‖ϕh − ϕ‖
2
H1
)
‖ϕh − ϕ‖
2
H1 ,
and for the terms involving Ψ′,
(Ψ′(ϕh)−Ψ
′(ϕ)−Ψ′′(ϕ)ξ, λ) = (Ψ′′(ϕ)Φ +RΨ(ϕh − ϕ)
2, λ)
≤ ‖Ψ′′(ϕ)‖L∞‖Φ‖L2‖λ‖L2 + ‖RΨ‖L6‖ϕh − ϕ‖
2
L6‖λ‖L2
≤
1
8
‖λ‖2L2 + C
(
1 + ‖ϕ‖4H2
)
‖Φ‖2L2 + C‖ϕh − ϕ‖
4
H1 ,
where we used (A2), (2.5) and (4.12). Lastly, we tackle the term involving Xh. First, we
observe with the assumption g ∈W 2,∞(Rd×d,R) from (A6) that
|g(W,E (ϕh, E(uh)))− g(W,E (ϕ, E(u)))|
=
∣∣∣∣
ˆ 1
0
g′(zW,E(ϕh, E(uh)) + (1− z)W,E(ϕ, E(u))) dz : C(E(uh − u)− (ϕh − ϕ)E
∗)
∣∣∣∣
≤ C|E(uh)− E(u)|+ C|ϕh − ϕ|,
and
g(W,E (ϕh, E(uh)))− g(W,E (ϕ, E(u))) − g
′(W,E(ϕ, E(u))) : C(E(v)− ξE
∗)
= g′(W,E(ϕ, E(u))) : C(E(z) − ΦE
∗)
+
(ˆ 1
0
(1− z)g′′(·) dz
)
[C(E(uh − u)− (ϕh − ϕ)E
∗)] : [C(E(uh − u)− (ϕh − ϕ)E
∗)]
≤ g′(W,E(ϕ, E(u))) : C(E(z) − ΦE
∗) + C|C(E(uh − u)− (ϕh − ϕ)E
∗)|2,
where the fourth order tensor g′′(·) is evaluated at (1− z)W,E(ϕ, E(u))+ zW,E (ϕh, E(uh)).
Hence, using the boundedness of f(ϕ), g(·), g′(·), g′′(·), σ and σh that are independent of
‖h‖U , we obtain for a positive constant ε > 0 to be determined later,
(λpXh,Φ) ≤ ε‖Φ‖
2
H2 +C‖Xh‖
2
L1
≤ ε‖Φ‖2H2 +C‖E(uh)− E(u)‖
2
L2‖ϕh − ϕ‖
2
L4‖σh − σ‖
2
L4
+ C‖ϕh − ϕ‖
4
L4‖σh − σ‖
2
L2+C‖E(uh)− E(u)‖
2
L2
(
‖σh − σ‖
2
L2 + ‖ϕh − ϕ‖
2
L2
)
+ C‖ϕh − ϕ‖
4
L2 +C‖ϕh − ϕ‖
2
L2‖σh − σ‖
2
L2 + C‖Φ‖
2
L2
+ C‖θ‖2L2 + C‖E(z)‖
2
L2 + C‖E(uh)− E(u)‖
4
L2
≤ ε‖Φ‖2H2 +C(‖h‖
4
U + ‖h‖
6
U ).
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To close the estimate we require an estimate for ‖Φ‖2H2 , which can be obtained from
(4.11b). Using that (Φ, λ, θ,z) ∈ Yβlin we see that
‖∆Φ‖2L2 ≤ C‖λ‖
2
L2 + C‖Ψ
′(ϕh)−Ψ
′(ϕ)−Ψ′′(ϕ)ξ‖2L2 + C‖θ‖
2
L2 + C‖E(z)‖
2
L2 + C‖Φ‖
2
L2
≤ C
(
1 + ‖ϕ‖4H2
)
‖Φ‖2L2 + C‖h‖
4
U + C
(
‖θ‖2L2 + ‖E(z)‖
2
L2 + ‖λ‖
2
L2
)
.
By elliptic regularity, there exists a positive constant C0 independent of (Φ, λ, θ,z) and h,
as well as M and K, such that
‖Φ‖2H2 ≤ C
(
1 + ‖ϕ‖4H2
)
‖Φ‖2L2 + C‖h‖
4
U + C0
(
‖θ‖2L2 + ‖E(z)‖
2
L2 + ‖λ‖
2
L2
)
. (4.14)
Let α be a positive constant such that
αC0 ≤
1
8 .
Multiplying (4.14) with α and adding to (4.13), then employing the estimates for the
right-hand side and choosing ε = α2 , we obtain
1
2
d
dt
(
‖Φ‖2L2 + βM‖θ‖
2
L2
)
+
1
2
‖λ‖2L2 +
α
2
‖Φ‖2H2
+M‖∇θ‖2L2 +MB‖θ‖
2
L2 +Mκ‖θ‖
2
L2
Γ
− Cˆ‖θ‖2L2 + (Kc0 − Cˆ)‖E(z)‖
2
L2
≤ C
(
1 + ‖ϕ‖4H2
)
‖Φ‖2L2 + C‖ϕh − ϕ‖
2
H1
(
|h2|
2 + |h3|
2
)
+ C‖ϕh − ϕ‖
2
H1
(
‖σh − σ‖
2
H1 + ‖ϕh − ϕ‖
2
H1 + ‖E(uh)− E(u)‖
2
L2
)
+ C‖E(uh)− E(u)‖
2
L2
(
‖E(uh)− E(u)‖
2
L2 + ‖σh − σ‖
2
L2
)
+C(‖h‖4U + ‖h‖
6
U )
=: C
(
1 + ‖ϕ‖4H2
)
‖Φ‖2L2 +C‖ϕh − ϕ‖
2
H1
(
|h2|
2 + |h3|
2
)
+Rh,
where the positive constants Cˆ appearing on the left-hand side are independent of M and
K. Hence, choosing M and K sufficiently large, with Gronwall’s inequality and Korn’s
inequality, as well as Φ(0) = θ(0) = 0, we have
‖Φ‖2L∞(0,T ;L2) + β‖θ‖
2
L∞(0,T ;L2) + ‖λ‖
2
L2(Q) + ‖Φ‖
2
L2(0,T ;H2)
+ ‖θ‖2L2(0,T ;H1) + ‖z‖
2
L2(0,T ;X(Ω))
≤ C exp
(
C + C‖ϕ‖4L4(0,T ;H2)
) ˆ T
0
‖ϕh − ϕ‖
2
H1
(
|h2|
2 + |h3|
2
)
+Rh dt
≤ C(‖h‖4U + ‖h‖
6
U ),
where the last inequality comes from the application of (2.5). This completes the proof
as (4.10) has been shown.
4.3 Adjoint system
Associated to an optimal control w∗ ∈ Uad and its corresponding solution (ϕ, µ, σ,u) are
the adjoint variables (p, q, r, s) that satisfies the following adjoint system written in strong
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form:
f1 = −pt −∆q + G in Q, (4.15a)
q = −∆p in Q, (4.15b)
0 = −βrt −∆r +Br +K in Q, (4.15c)
f2 = div(C(E(s) +H)) in Q, (4.15d)
p(T ) = αΩ(ϕ(T )− ϕΩ), r(T ) = 0 in Ω, (4.15e)
0 = ∂np = ∂nq, ∂nr + κr = 0 on Σ, (4.15f)
0 = (C(E(s) +H)− f2)n on ΣD, (4.15g)
s = 0 on ΣN , (4.15h)
where using the notation n′(·, ϕ) = ∂n∂ϕ (·, ϕ),
f1 = f1(ϕ, E(u)) = αQ(ϕ− ϕQ) +
αE
2 n
′(·, ϕ)|W,E (ϕ, E(u))|
2
− αEn(·, ϕ)W,E (ϕ, E(u)) : CE
∗,
f2 = f2(ϕ, E(u)) = −div(αEn(·, ϕ)CW,E (ϕ, E(u))),
G = G(ϕ, σ, E(u), p, q, r, E(s), w∗2 , w
∗
3) = Ψ
′′(ϕ)q + (λa + w
∗
2)k
′(ϕ)p + qCE∗ : E∗
− λpσp
(
f ′(ϕ)g(W,E (ϕ, E(u))) + f(ϕ)g
′(W,E(ϕ, E(u))) : CE
∗
)
+ h′(ϕ)(λcσ −w
∗
3)r + CE
∗ : E(s),
K = K(ϕ, E(u), p, q, r) = h(ϕ)λcr − λpf(ϕ)g(W,E (ϕ, E(u)))p − χq,
H = H(ϕ, σ, E(u), p, q) = qE∗ + λppσf(ϕ)g
′(W,E(ϕ, E(u))).
We introduce the solution space
Zβ =


H1(0, T ;H2
n
(Ω)′) ∩ L2(0, T ;H2
n
(Ω))× L2(Q)
×H1(0, T ;H1(Ω)′) ∩ L2(0, T ;H1(Ω))× L2(0, T ;X(Ω)) if β > 0,
H1(0, T ;H2
n
(Ω)′) ∩ L2(0, T ;H2
n
(Ω))× L2(Q)
×L2(0, T ;H1(Ω))× L2(0, T ;X(Ω)) if β = 0.
Theorem 6. For given w∗ ∈ Uad with (ϕ, µ, σ,u) = S(w
∗) ∈ Yβ , under (A1)-(A8),
there exists a unique solution (p, q, r, s) ∈ Zβ to the adjoint system (4.15) with p(T ) =
αΩ(ϕ(T )− ϕΩ), r(T ) = 0 if β > 0, and
0 =
ˆ T
0
−〈pt, ζ〉H2 − (q,∆ζ) + (G − f1, ζ) dt, (4.16a)
0 =
ˆ T
0
−(q, φ) + (∇p,∇φ) dt, (4.16b)
0 =
ˆ T
0
β〈−rt, φ〉+ (∇r,∇φ) + (Br, φ) + κ(r, φ)Γ + (K, φ) dt, (4.16c)
0 =
ˆ T
0
(C(E(s) +H),∇η)− (f2,η) dt, (4.16d)
for all ζ ∈ L2(0, T ;H2
n
(Ω)), φ ∈ L2(0, T ;H1(Ω)) and η ∈ L2(0, T ;X(Ω)).
Remark 4.1. Let us notice that the test function space H2
n
(Ω) in (4.16a) can be weakened
by assuming a more regular target function ϕΩ. In fact, formally testing (4.16a) by q and
(4.16b) by pt will lead to the regularity q ∈ L
2(0, T ;H1(Ω)), and p ∈ L∞(0, T ;H1(Ω))
provided p(T ) = αΩ(ϕ(T ) − ϕΩ) ∈ H
1(Ω), which is fulfilled if ϕΩ ∈ H
1(Ω).
18
Proof. We proceed with formal estimates that can be rigorously derived with a standard
Galerkin approximation and let us note that in the following positive constants denoted
by the symbol C will be independent of the Galerkin parameter. Then, testing ζ = Kp
in (4.16a), φ = −Kq and φ = p in (4.16b), φ = Hr in (4.16c) and η = Zs in (4.16d) for
some positive constants K, H and Z yet to be determined, we obtain after summing the
resulting equalities
−
1
2
d
dt
(
K‖p‖2L2 +Hβ‖r‖
2
L2
)
+K‖q‖2L2 + ‖∇p‖
2
L2
+H‖∇r‖2L2 +Hκ‖r‖
2
L2
Γ
+HB‖r‖2L2 + Zc0‖E(s)‖
2
L2
≤ −(K(G − f1), p)+(q, p)− (HK, r) − (Z(CH − f2), E(s)).
(4.17)
Firstly, we obtain from (4.16b) and elliptic regularity that
‖p‖2H2 ≤ C‖∆p‖
2
L2 + C‖p‖
2
L2 ≤ C‖q‖
2
L2 + C‖p‖
2
L2 . (4.18)
Then, a short calculation shows that
(K(G − f1), p) ≤ ‖q‖
2
L2 + C
(
1 + ‖Ψ′′(ϕ)‖2L∞
)
‖p‖2L2 +C‖r‖
2
L2
+C‖ϕ‖2L2 + C‖E(s)‖
2
L2 +
1
2‖p‖
2
H2 + C‖ϕ− ϕQ‖
2
L2 ,
(q, p) ≤ ‖q‖2L2 + C‖p‖
2
L2 ,
(HK, r) ≤ H2‖q‖2L2 + C
(
‖r‖2L2 + ‖p‖
2
L2
)
,
(Z(CH − f2), E(s)) ≤ Z
2‖q‖2L2 + CZ
2
(
‖p‖2L2 + ‖ϕ‖
2
L2 + ‖E(u)‖
2
L2
)
+ C‖E(s)‖2L2 ,
with positive constants C independent of H and Z. Adding (4.18) to (4.17) and substi-
tuting the above yields
−
1
2
d
dt
(
K‖p‖2L2 +Hβ‖r‖
2
L2
)
+ (K − (1 + C +H2 + Z2))‖q‖2L2 +
1
2‖p‖
2
H2
+H‖∇r‖2L2 +Hκ‖r‖
2
L2
Γ
+ (HB − C)‖r‖2L2 + (Zc0 − C)‖E(s)‖
2
L2
≤ C
(
1 + ‖ϕ‖4H2
)
‖p‖2L2 + C‖ϕ− ϕQ‖
2
L2 +C
(
‖ϕ‖2L2 + ‖E(u)‖
2
L2
)
.
If B > 0, we choose HB > C, otherwise we use the generalised Poincare´ inequality with
H sufficiently large so that
H‖∇r‖2L2 +Hκ‖r‖
2
L2
Γ
≥ (C + 1)‖r‖2L2 .
Then, choosing Z sufficiently large so that Zc0 > C, and then finally K sufficiently large,
we obtain via Gronwall’s inequality (applied backwards in time) and Korn’s inequality
that
‖p‖2L∞(0,T ;L2) + β‖r‖
2
L∞(0,T ;L2) + ‖q‖
2
L2(Q)
+ ‖p‖2L2(0,T ;H2) + ‖r‖
2
L2(0,T ;H1) + ‖s‖
2
L2(0,T ;X(Ω))
≤ C‖ϕ− ϕQ‖
2
L2(Q) + C‖ϕ‖
2
L2(Q) +C‖E(u)‖
2
L2(Q).
(4.19)
Then, from (4.16a) we infer
‖pt‖L2(0,T ;H2
n
(Ω)′) ≤ C
(
1 + ‖Ψ′′(ϕ)‖L∞(0,T ;L2)
)
‖q‖L2(Q) + C‖p‖L2(Q) + C‖r‖L2(Q),
and if β > 0, a comparison of terms in (4.16c) gives
‖rt‖L2(0,T ;H1(Ω)′) ≤ C‖r‖L2(0,T ;H1) + C‖p‖L2(Q) + C‖q‖L2(Q).
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These estimates are sufficient to pass to the limit and deduce the existence of a solution
(p, q, r, s) ∈ Zβ to (4.15) in the sense that (4.16) is fulfilled. Moreover, as the adjoint
system is linear in (p, q, r, s), the difference of any two solutions satisfy (4.16) where the
terms involving n(·, ϕ) and ϕ − ϕQ are absent in f1 and f2. Consequently, we arrive at
an analogue of (4.19) for the difference of two solutions where the right-hand side is zero,
which in turn leads to uniqueness of solutions.
4.4 Optimality conditions
Lastly, we exploit the differentiability property of S established so far to obtain the first-
order necessary conditions for optimality. In this direction, we first express the reduced
cost functional J as the sum
J (w) := J1(w) + J2(w),
where
J1(w) =
αΩ
2
‖S1(w)− ϕΩ‖
2
L2(Ω) +
αQ
2
‖S1(w)− ϕQ‖
2
L2(Q)
+
αE
2
ˆ
Q
n(x,S1(w))|W,E(S1(w), E(S4(w)))|
2 dx dt
+
γ1
2
‖w1‖
2
L2(Σ) +
γ2
2
‖w2‖
2
L2(0,T ) +
γ3
2
‖w3‖
2
L2(0,T ),
J2(w) = γ4‖w2‖L1(0,T ) + γ5‖w3‖L1(0,T ).
Then, for arbitrary y ∈ Uad and an optimal control w
∗ ∈ Uad with corresponding state
(ϕ, µ, σ,u) = S(w∗) ∈ Yβ and linearised state variables (ξ, η, ψ,v) ∈ Yβlin to (4.4) corre-
sponding to h = y−w∗, the differentiability of the solution operator S : U → Yβ and the
chain rule shows that
DJ1(w
∗)[h] = DJ1(w
∗)[y −w∗]
=
ˆ
Ω
αΩ(ϕ(T )− ϕΩ)ξ(T ) dx+
ˆ
Q
αQ(ϕ− ϕQ)ξ dx dt
+ αE
ˆ
Q
1
2n
′(x, ϕ)ξ|W,E |
2 + n(x, ϕ)W,E : C(E(v)− ξE
∗) dx dt
+
ˆ T
0
γ1(w
∗
1 , h1)Γ dt+
ˆ T
0
γ2w
∗
2h2 + γ3w
∗
3h3 dt,
(4.20)
whereW,E is evaluated at (ϕ, E(u)). On the other hand, optimality ofw
∗ and the convexity
of J2 leads to
0 ≤ J (w∗ + t(y −w∗))− J (w∗)
= J1(w
∗ + t(y −w∗))−J1(w
∗) + J2((1− t)w
∗ + ty)− J2(w
∗)
≤ J1(w
∗ + t(y −w∗))−J1(w
∗) + t[J2(y)− J2(w
∗)]
for all t ∈ (0, 1) and arbitrary y ∈ Uad. Dividing by t and passing to the limit t→ 0 yields
the inequality
0 ≤ DJ1(w
∗)[y −w∗] + J2(y)− J2(w
∗) ∀y ∈ Uad. (4.21)
Arguing as in [41, Sec. 3 and 4], the inequality (4.21) allows us to interpret w∗ as a solution
to the convex minimisation problem
min
y∈U
(
DJ1(w
∗)[y] + J2(y) + IUad(y)
)
where IUad(y) =
{
0 if y ∈ Uad,
+∞ otherwise,
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denotes the indicator function of the set Uad. Using the definition of subdifferentials, the
inequality (4.21) can also be interpreted as
0 ∈ ∂
(
DJ1(w
∗) + J2 + IUad
)
(w∗) = {DJ1(w
∗)}+ ∂J2(w
∗) + ∂IUad(w
∗),
where the equality is due to the well-known sum rule for subdifferentials of convex func-
tionals. This implies there exist elements ζ ∈ ∂IUad(w
∗), and λ2(t) ∈ ∂‖w
∗
2(t)‖L1(0,T ),
λ3(t) ∈ ∂‖w
∗
3(t)‖L1(0,T ) with λ2, λ3 ∈ L
∞(0, T ) satisfy (4.1) for a.e. t ∈ (0, T ), see, e.g.,
[41, Sec. 4.2] for similar ideas regarding the derivation, such that
0 = DJ1(w
∗) + λ+ ζ
for λ = (0, γ4λ2, γ5λ3)
⊤. From the definition of ∂IUad we have
(ζ,y −w∗) ≤ IUad(y)− IUad(w
∗) = 0 as y,w∗ ∈ Uad,
where we use (·, ·) to denote the inner product on U . Hence, from (4.21) we deduce that
w∗ ∈ Uad satisfies
0 ≤ DJ1(w
∗)[y −w∗] + (λ,y −w∗) ∀y ∈ Uad. (4.22)
Next, we aim to simplify (4.20) with the help of the adjoint variables. The standard
procedure is to test (4.4a) with ζ = p, (4.4b) with ζ = −q, (4.4c) with ζ = r, (4.4d) with
η = s, then take the sum and compare with the resulting equality obtained from the sum
of (4.16a) with ζ = ξ, (4.16b) with φ = η, (4.16c) with φ = ψ and (4.16d) with η = −v,
which yields the relations
ˆ T
0
κ(h1, r)Γ + (h3h(ϕ), r) − (h
′(ϕ)ξ(λcσ −w
∗
3), r) dt
=
ˆ T
0
(λpf(ϕ)g(W,E (ϕ, E(u)))p, ψ) − (χq, ψ) dt,
and
αQ
ˆ
Q
(ϕ− ϕQ)ξ dx dt+ αΩ
ˆ
Ω
(ϕ(T ) − ϕΩ)ξ(T ) dx
+
ˆ
Q
αE
2
n′(x, ϕ)ξ|W,E (ϕ, E(u))|
2 + αEn(x, ϕ)W,E (ϕ, E(u)) : C(E(v)− ξE
∗) dx dt
=
ˆ T
0
(h′(ϕ)(λcσ − w
∗
3)r, ξ)− (h2k(ϕ), p) − (χψ, q) dt
+
ˆ T
0
(λpf(ϕ)ψg(W,E (ϕ, E(u))), p) dt.
Combining these two leads to the simplification
DJ1(w
∗)[h] =
ˆ T
0
κ(h1, r)Γ − h2(k(ϕ), p) + h3(h(ϕ), r) dt
+
ˆ T
0
γ1(w
∗
1 , h1)Γ dt+
ˆ T
0
γ2w
∗
2h2 + γ3w
∗
3h3 dt,
and (4.2) is then a consequence of (4.22).
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5 Sparsity of non-negative optimal controls
In the medical context, the control variables w2 = m(t) and w3 = s(t) should be non-
negative, and so we modify the admissible control subsets U
(2)
ad and U
(3)
ad to the following
U
(i)
ad = {wi ∈ L
∞(0, T ) : 0 ≤ wi(t) ≤ w for a.e. t ∈ (0, T )} for i = 2, 3, (5.1)
where w is a fixed positive constant. If γ1 > 0, from the optimality condition (4.2),
substituting y2 = w
∗
2 and y3 = w
∗
3, then using the Hilbert projection theorem allows us
to infer that w∗1 is the L
2(Σ)-orthogonal projection of −κr/γ1 onto the closed and convex
subset U
(1)
ad of L
2(Σ), leading to the representation formula
w∗1(x, t) = min
(
w1(x, t), max
(
w1(x, t), −
κ
γ1
r(x, t)
) )
for a.e. (x, t) ∈ Σ.
In a similar fashion, if γ2, γ4 > 0, substituting y1 = w
∗
1 and y3 = w
∗
3 in (4.2) leads to
representation formula
w∗2(t) = P[0,w]
(
1
γ2
(ˆ
Ω
k(ϕ(x, t))p(x, t) dx − γ4λ2(t)
))
for a.e. t ∈ (0, T ), (5.2)
where P[a,b] : R→ [a, b] denotes the pointwise projection function
P[a,b](s) = min(b, max(a, s)).
Similarly, if γ3, γ5 > 0, then substituting y1 = w
∗
1 and y2 = w
∗
2 in (4.2) leads to represen-
tation formula
w∗3(t) = P[0,w]
(
−
1
γ3
(
γ5λ3(t) +
ˆ
Ω
h(ϕ(x, t))r(x, t) dx
))
for a.e. t ∈ (0, T ).
Due to the L1-regularisation for w2 and w3 in the optimal control problem, we can expect
the optimal controls w∗2 and w
∗
3 to vanish on certain parts of the time interval [0, T ]. This
is formulated as follows.
Theorem 7. Under (A1)-(A8), let w∗ = (w∗1, w
∗
2 , w
∗
3) ∈ Uad be an optimal control where
U
(2)
ad and U
(3)
ad are now given as (5.1) with the associated state (ϕ, µ, σ,u) = S(w
∗) and
adjoint variables (p, q, r, s). Then, we have the following characterisations:
• If γ2, γ4 > 0, for a.e. t ∈ (0, T ),
w∗2(t) = 0 ⇐⇒
ˆ
Ω
k(ϕ(x, t))p(x, t) dx ≤ γ4. (5.3)
• If γ3, γ5 > 0, for a.e. t ∈ (0, T ),
w∗3(t) = 0 ⇐⇒
ˆ
Ω
h(ϕ(x, t))r(x, t) dx ≥ −γ5. (5.4)
Remark 5.1. Similar one-sided inequalities characterising sparsity of optimal controls
are common when the lower bound in the admissible control sets U
(i)
ad is zero, see, e.g.,[6,
Thm. 3.1] or [7, Thm. 3.3]. If we allow w2(t), w3(t) in the definition (2.2) of U
(2)
ad and U
(3)
ad
to be a negative constant w, then it is possible to provide a representation formula also for
λ2 and λ3, see [41] in the context of Cahn–Hilliard tumour models, and also [6, 7, 42] for
classical parabolic and elliptic control problems. However, a negative lower bound for the
controls may not be applicable in a medical context.
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Remark 5.2. We point out that if w∗2(t0) = 0 for some t0 ∈ (0, T ), then there exists
an open subinterval I ⊂ (0, T ) with t0 ∈ I such that w
∗
2(t) = 0 for all t ∈ I. The same
assertion also holds for w∗3 provided β > 0. This is due to the fact that the mappings
t 7→
ˆ
Ω
k(ϕ(x, t))p(x, t) dx,
t 7→
ˆ
Ω
h(ϕ(x, t))r(x, t) dx if β > 0,
are continuous in light of the regularities ϕ ∈ C0([0, T ];L2(Ω)) from Theorem 1, p ∈
C0([0, T ];L2(Ω)) and r ∈ C0([0, T ];L2(Ω)) if β > 0 from Theorem 6. In particular,
this behaviour where the optimal controls are zero over an interval is consistent with the
prevailing medical practice in which there are periods in the overall treatment where radi-
ation/cytotoxic therapies are not applied to patients.
Proof. Let us just present the details for (5.3), as (5.4) can be derived in an analogous
manner. Due to the modification to U
(2)
ad , we observe from (4.1) that λ2(t) ∈ L
∞(0, T )
satisfies
λ2(t) ∈
{
{1} if w∗2(t) > 0,
[−1, 1] if w∗2(t) = 0,
(5.5)
for a.e. t ∈ (0, T ). The left implication proceeds as follows: Consider the set E = {t ∈
(0, T ) : w∗2(t) = 0}, where by the representation formula (5.2), we see thatˆ
Ω
k(ϕ(x, t))p(x, t) dx − γ4λ2(t) ≤ 0 for all t ∈ E.
Using (5.5) and rearranging, we obtain the left implication of (5.3). For the right impli-
cation we argue by contrapositive: Suppose w∗2(t) > 0, then from (5.5) we have λ2(t) = 1
and thus by the representation formula it holds that
ˆ
Ω
k(ϕ(x, t))p(x, t) dx − γ4λ2(t) =
ˆ
Ω
k(ϕ(x, t))p(x, t) dx − γ4 > 0.
Upon rearranging we obtain the assertion
w∗2(t) > 0 =⇒
ˆ
Ω
k(ϕ(x, t))p(x, t) dx > γ4,
which gives the right implication of (5.3).
An interesting consequence is that we can identify w∗2(t) ≡ 0 as a local optimal control
provided γ4 is sufficiently large, and similarly w
∗
3(t) ≡ 0 is a local optimal control provided
γ5 is sufficiently large.
Corollary 5.1. Suppose (A1)-(A8) and γ2 > 0. Then there exists γ∗ > 0 such that for
γ4 > γ∗, w
∗
2(t) ≡ 0 for all t ∈ (0, T ) is an optimal control for (1.4). Similarly, suppose
γ3 > 0 and β > 0, then there exists γ
∗ > 0 such that for γ5 > γ
∗, w∗3(t) ≡ 0 for all
t ∈ (0, T ) is an optimal control for (1.4).
Proof. It suffices to use conditions (5.3) and (5.4). In light of the admissible control subsets
defined in (5.1), where w is a fixed constant, the constant K1 in (2.4) is independent of
the weights {αQ, αΩ, αE , γ1, γ2, γ3, γ4, γ5} in the optimal control problem (1.4). Then,
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revisiting the proof of Theorem 6, we note that {γi}
5
i=1 do not appear in the adjoint
system (4.15). Consequently, the positive constants on the right-hand side of (4.19) are
independent of {γi}
5
i=1. Employing (A3) on the boundedness of h and k, we deduce thatˆ
Ω
k(ϕ(x, t))p(x, t) dx ≤ C1 for a.e. t ∈ (0, T ),ˆ
Ω
h(ϕ(x, t))r(x, t) dx ≥ −C2 for a.e. t ∈ (0, T ) if β > 0,
for positive constants C1 and C2 independent of {γi}
5
i=1. The assertion now follows from
(5.3) and (5.4) by choosing γ∗ = C1 and γ
∗ = C2.
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